Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma

Am J Hematol. 2020 Sep;95(9):E232-E235. doi: 10.1002/ajh.25858. Epub 2020 Jun 10.

Authors

Elisabet E Manasanch¹, Preetesh Jain¹, Wendy Chen¹, Onyeka Oriabure¹, Maria Badillo¹, Lei Feng², Zuzana Berkova¹, Robert Z Orlowski^{1

3}, Michael Wang¹

Affiliations

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 32390148
DOI: 10.1002/ajh.25858

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Dexamethasone / administration & dosage
Disease-Free Survival
Female
Granulocyte Colony-Stimulating Factor / administration & dosage
Humans
Male
Middle Aged
Multiple Myeloma* / drug therapy
Multiple Myeloma* / mortality
Recurrence
Survival Rate
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives

Substances

Granulocyte Colony-Stimulating Factor
Thalidomide
Dexamethasone
pomalidomide

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States